<DOC>
	<DOCNO>NCT00407407</DOCNO>
	<brief_summary>The primary purpose study determine maximum tolerate dose dose-limiting toxicity ( DLTs ) weekly every 3-weeks ABI-007 combination carboplatin ( area curve [ AUC ] =6 ) patient ovarian cancer , primary peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>ABI-007 With Carboplatin First-Line Therapy Patients With Epithelial Ovarian , Primary Peritoneal , Fallopian Tube Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Patients histological diagnosis primary peritoneal carcinoma , fallopian tube epithelial ovarian carcinoma ( Stage III IV ) either ( optimal less equal 1 cm ) residual disease suboptimal residual disease follow initial appropriate surgery . Patients follow histologically confirm type ovarian cancer eligible : serous cystadenocarcinoma , mucinous cystadenocarcinoma , clear cell adenocarcinoma , adenocarcinoma ( unspecified ) , malignant Brenner 's tumor , endometrioid adenocarcinoma , undifferentiated carcinoma , mixed epithelial carcinoma transitional cell carcinoma . Patients extraovarian papillary serous cystadenocarcinoma eligible . Patients measurable disease may include assessed toxicity progressionfree survival . Measurable disease NOT require present follow assess response . For patient evaluate response measurable disease , tumor must great equal 2.0 cm conventional compute tomography ( CT ) image great equal 1.0 cm spiral CT imaging . No prior chemotherapy ovarian cancer permit . Patients must enter 12 week postoperatively . ECOG performance status 02 . Age great equal 18 year . Patient follow blood count Baseline : ANC great equal 1.5 x 10^9 cells/L ; Platelets great equal 100 x 10^9 cells/L ; Hemoglobin ( Hgb ) great equal 9 g/dL . Patient follow blood chemistry level Baseline : AST ( SGOT ) , ALT ( SGPT ) less equal 2.5x upper limit normal range ( ULN ) ; Total bilirubin less equal ULN ; Creatinine le equal 1.5 mg/dL . Peripheral neuropathy Grade 0 1 National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) . It assume almost patient already bilateral oophorectomy . However , female childbearing potential , negative pregnancy test ( within 72 hour first dose study drug ) , patient must agree use effective method avoid pregnancy duration study . Patients must sign approve informed consent authorization permit release personal health information . Patients receive prior treatment , initial debulking surgery , cancer treat study . Patients may receive adjuvant chemotherapy localize breast cancer , therapy complete great equal 3 year registration study patient remain free recurrent metastatic disease . Patients receive prior radiotherapy portion abdominal cavity pelvis . Prior radiation localize cancer breast , head neck skin permit complete great equal 3 year registration study patient remain free recurrent metastatic disease . Concurrent immunotherapy hormonal therapy ovarian cancer . Parenchymal brain metastasis , unless document clinically radiographically stable least 6 month treatment disease . Serious intercurrent medical psychiatric illness , include serious active infection ( i.e . require antibiotic ) . Patients borderline low malignant potential tumor . History malignancy within last 5 year , could affect diagnosis assessment ovarian cancer . Patients receive investigational drug within previous 3 week . Patient currently enrol different clinical study investigational procedure perform investigational therapy administer . Also , patient may enroll clinical trial participate study . Pregnant nursing woman . Patients unstable angina myocardial infarction within past 6 month . Patients evidence cardiac conduction abnormality ( e.g. , bundle branch block , heart block ) eligible cardiac status stable 6 month prior study entry . Patients prior hypersensitivity Taxol Taxotere .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Epithelial ovarian</keyword>
	<keyword>Primary peritoneal fallopian tube carcinoma</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Carboplatin</keyword>
</DOC>